http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20221037-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-173
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-173
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
filingDate 2020-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d16bb8c1c157a33062407b2795be56a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9be7694cb3953ae779008e15d54d57a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20226dbb3a41d182d9a30e3078330b05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2eececf73907062e927b5de7d3614c86
publicationDate 2022-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PE-20221037-A1
titleOfInvention ANTIVIRAL PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF
abstract It refers to 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) diesters of Formula II, wherein: R1 and R2 are -C(=O)R3 and R3 is isopropyl, 3-pentyl, cyclopentyl, phenyl or phenylmethyl. Among the preferred compounds we have the following: (2R,3S,5R)-5-(6-amino-2-fluoro-9Hpurin-9-yl)-2-(((2-ethylbutanoyl)oxy)methyl 2-ethylbutanoate )-2-ethynyltetrahydrofuran-3-yl; (2R,3S,5R)-5-(6-amino-2-fluoro-9Hpurin-9-yl)-2-ethynyl-2-((2-phenylacetoxy)methyl)tetrahydrofuran-3-yl 2-phenylacetate; among others. These compounds are crystalline and useful in providing extended in vivo viral suppression of human immunodeficiency virus (HIV).
priorityDate 2019-09-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456464034
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394837
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409407841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393661
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6483431

Total number of triples: 38.